Oxford Biomedica plc, a gene and cell therapy group, has appointed Dr. Siyamak (“Sam”) Rasty to the group’s board as a non-executive Director.
Dr. Rasty brings with him more than two decades of experience across biopharma leadership roles in R&D and commercial development.
He is currently president and CEO of US cell-based therapeutics company PlateletBio. Prior to this, he was COO at Homology Medicines, Inc., a genetic medicines company that he helped launch in 2016.
He has previously held senior positions at Shire Pharmaceuticals (including as Vice President and Head of New Products) Director of Corporate Development at Endo Pharmaceuticals, and Director of Portfolio Management, Business & Commercial Analysis and Global Commercial Strategy at GlaxoSmithKline.
Dr. Rasty holds a Ph.D. in Biochemistry from Louisiana State University, where he focused on transcriptional regulation of lentiviruses, completed a postdoctoral fellowship in Molecular Genetics and Biochemistry at the University of Pittsburgh School of Medicine, and received an MBA from Villanova University.